183 related articles for article (PubMed ID: 23266353)
21. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women.
Maruyama N; Miyoshi Y; Taguchi T; Tamaki Y; Monden M; Noguchi S
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):408-14. PubMed ID: 17202311
[TBL] [Abstract][Full Text] [Related]
22. The frequencies and clinical implications of mutations in 33 kinase-related genes in locally advanced rectal cancer: a pilot study.
Abdul-Jalil KI; Sheehan KM; Toomey S; Schmid J; Prehn J; O'Grady A; Cummins R; O'Neill B; McNamara DA; Deasy J; Breathnach O; Grogan L; Rogers A; Doherty G; Winter D; Ryan J; El-Masry S; Gibbons D; Sheahan K; Gillen P; Kay EW; Hennessy BT
Ann Surg Oncol; 2014 Aug; 21(8):2642-9. PubMed ID: 24700299
[TBL] [Abstract][Full Text] [Related]
23. PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers.
Castaneda CA; Lopez-Ilasaca M; Pinto JA; Chirinos-Arias M; Doimi F; Neciosup SP; Rojas KI; Vidaurre T; Balko JM; Arteaga CL; Gomez HL
Hematol Oncol Stem Cell Ther; 2014 Dec; 7(4):142-8. PubMed ID: 25467032
[TBL] [Abstract][Full Text] [Related]
24. Tumor diameter and volume assessed by magnetic resonance imaging in the prediction of outcome for invasive cervical cancer.
Wagenaar HC; Trimbos JB; Postema S; Anastasopoulou A; van der Geest RJ; Reiber JH; Kenter GG; Peters AA; Pattynama PM
Gynecol Oncol; 2001 Sep; 82(3):474-82. PubMed ID: 11520143
[TBL] [Abstract][Full Text] [Related]
25. Predictive value of diffusion-weighted magnetic resonance imaging during chemoradiotherapy for uterine cervical cancer.
Makino H; Kato H; Furui T; Morishige K; Kanematsu M
J Obstet Gynaecol Res; 2014 Apr; 40(4):1098-104. PubMed ID: 24320754
[TBL] [Abstract][Full Text] [Related]
26. PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients.
Lai YL; Mau BL; Cheng WH; Chen HM; Chiu HH; Tzen CY
Ann Surg Oncol; 2008 Apr; 15(4):1064-9. PubMed ID: 18183466
[TBL] [Abstract][Full Text] [Related]
27. Application of tumor markers CEA, TPA, and SCC-Ag in patients with low-risk FIGO stage IB and IIA squamous cell carcinoma of the uterine cervix.
Juang CM; Wang PH; Yen MS; Lai CR; Ng HT; Yuan CC
Gynecol Oncol; 2000 Jan; 76(1):103-6. PubMed ID: 10620449
[TBL] [Abstract][Full Text] [Related]
28. Prognostic factors in pathologic parametrium-positive patients with stage IB-IIB cervical cancer treated by radical surgery and adjuvant therapy.
Kodama J; Seki N; Nakamura K; Hongo A; Hiramatsu Y
Gynecol Oncol; 2007 Jun; 105(3):757-61. PubMed ID: 17433424
[TBL] [Abstract][Full Text] [Related]
29. Glucose as a prognostic factor in non-diabetic women with locally advanced cervical cancer (IIB-IVA).
Lee YY; Choi CH; Kim CJ; Song TJ; Kim MK; Kim TJ; Lee JW; Kim BG; Lee JH; Bae DS
Gynecol Oncol; 2010 Mar; 116(3):459-63. PubMed ID: 20004008
[TBL] [Abstract][Full Text] [Related]
30. Outcome of stage IVA cervical cancer patients with disease limited to the pelvis in the era of chemoradiation: a Gynecologic Oncology Group study.
Rose PG; Ali S; Whitney CW; Lanciano R; Stehman FB
Gynecol Oncol; 2011 Jun; 121(3):542-5. PubMed ID: 21420157
[TBL] [Abstract][Full Text] [Related]
31. [Effects of pre-chemotherapy hemoglobin and platelet levels in patients with stage Ib2-IIb cervical cancer treated with neoadjuvant chemotherapy followed by radical hysterectomy].
Wang D; Wu M; Ren T; Wan XR; Feng FZ; Huang HF; Yang JX; Shen K; Xiang Y
Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):577-81. PubMed ID: 23141176
[TBL] [Abstract][Full Text] [Related]
32. PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast.
Li H; Zhu R; Wang L; Zhu T; Li Q; Chen Q; Wang H; Zhu H
Exp Mol Pathol; 2010 Feb; 88(1):150-5. PubMed ID: 19818761
[TBL] [Abstract][Full Text] [Related]
33. Mutational analysis of anal cancers demonstrates frequent PIK3CA mutations associated with poor outcome after salvage abdominoperineal resection.
Cacheux W; Rouleau E; Briaux A; Tsantoulis P; Mariani P; Richard-Molard M; Buecher B; Dangles-Marie V; Richon S; Lazartigues J; Jeannot E; Farkhondeh F; Sastre-Garau X; de La Rochefordière A; Labib A; Falcou MC; Stevens D; Roth A; Roman-Roman S; Mitry E; Bièche I; Lièvre A
Br J Cancer; 2016 Jun; 114(12):1387-94. PubMed ID: 27219019
[TBL] [Abstract][Full Text] [Related]
34. Concurrent chemoradiotherapy with nedaplatin after radical hysterectomy in patients with stage IB and II cervical cancer.
Kobayashi Y; Ohara T; Wada Y; Okuda Y; Kondo H; Okuma Y; Suzuki N; Gomi H; Kiguchi K; Ishizuka B
J Obstet Gynaecol Res; 2009 Jun; 35(3):490-4. PubMed ID: 19527388
[TBL] [Abstract][Full Text] [Related]
35. Difference in prognostic factors between stage IB and II uterine cervical carcinoma patients treated with radical hysterectomy and postoperative radiation therapy.
Niibe Y; Karasawa K; Kaizu T; Mizutani K; Ozaki Y; Nagano H; Ueda K; Murakami A; Tanaka Y
Radiat Med; 2002; 20(4):161-7. PubMed ID: 12296431
[TBL] [Abstract][Full Text] [Related]
36. PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients.
de la Rochefordiere A; Kamal M; Floquet A; Thomas L; Petrow P; Petit T; Pop M; Fabbro M; Kerr C; Joly F; Sevin E; Maillard S; Curé H; Weber B; Brunaud C; Minsat M; Gonzague L; Berton-Rigaud D; Aumont M; Gladieff L; Peignaux K; Bernard V; Leroy Q; Bieche I; Margogne A; Nadan A; Fourchotte V; Diallo A; Asselain B; Plancher C; Armanet S; Beuzeboc P; Scholl SM
Clin Cancer Res; 2015 Jun; 21(11):2530-7. PubMed ID: 25724520
[TBL] [Abstract][Full Text] [Related]
37. Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells.
Arjumand W; Merry CD; Wang C; Saba E; McIntyre JB; Fang S; Kornaga E; Ghatage P; Doll CM; Lees-Miller SP
Oncotarget; 2016 Dec; 7(50):82424-82439. PubMed ID: 27489350
[TBL] [Abstract][Full Text] [Related]
38. PIK3CA Somatic Mutation Status in Relation to Patient and Tumor Factors in Racial/Ethnic Minorities with Colorectal Cancer.
Phipps AI; Ahnen DJ; Cheng I; Newcomb PA; Win AK; Burnett T
Cancer Epidemiol Biomarkers Prev; 2015 Jul; 24(7):1046-51. PubMed ID: 25994739
[TBL] [Abstract][Full Text] [Related]
39. Expression of DNA damage response proteins in cervical cancer patients treated with radical chemoradiotherapy.
Ho CK; Kornaga EN; Klimowicz AC; Enwere EK; Dean M; Bebb GD; Phan T; Ghatage P; Magliocco AM; Lees-Miller SP; Doll CM
Gynecol Oncol; 2017 Apr; 145(1):176-184. PubMed ID: 28131528
[TBL] [Abstract][Full Text] [Related]
40. PIK3CA mutations predict recurrence in localized microsatellite stable colon cancer.
Manceau G; Marisa L; Boige V; Duval A; Gaub MP; Milano G; Selves J; Olschwang S; Jooste V; le Legrain M; Lecorre D; Guenot D; Etienne-Grimaldi MC; Kirzin S; Martin L; Lepage C; Bouvier AM; Laurent-Puig P
Cancer Med; 2015 Mar; 4(3):371-82. PubMed ID: 25641861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
